drugset
drugset / Trial / NCT04096950

Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury

NCT04096950 ↗

Phase 1 Completed 3 enrolled Tanabe Pharma America, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics of MT-3921 in subjects with spinal cord injury.

Timeline

Start
2020-04-19
Primary completion
2021-01-06
Completion
2021-01-06

Drugs

EvaluationDrugModalityDoseRoute
Subject UNASNEMAB Monoclonal antibody — Intravenous

Indications

spinal cord injury